Trial Outcomes & Findings for VA Video Connect in HIV Care (NCT NCT04055207)
NCT ID: NCT04055207
Last Updated: 2026-08-26
Results Overview
Completion of at least 1 visit with a primary care or Infectious Disease provider in each 6 months of the year at least 60 days apart.
Recruitment status
COMPLETED
Study phase
NA
Target enrollment
306 participants
Primary outcome timeframe
From enrollment to the end of follow-up at 12 months
Results posted on
2026-08-26
Participant Flow
Participants were enrolled at completion of a scheduled medical visit. The first participant was enrolled on July 1, 2021 and the last participant was enrolled on May 24, 2022.
Of 472 randomized scheduled clinic appointments, 306 appointments were completed and enrolled in the study.
Participant milestones
| Measure |
VVC Option
Option to receive VA Video Connect (VVC) delivery of HIV care.
VVC: Telehealth treatment is delivered via VA-approved technology to a patient's computer or mobile device.
|
Usual Care
All HIV care available at MEDVAMC will be delivered as usual.
|
|---|---|---|
|
Overall Study
STARTED
|
154
|
152
|
|
Overall Study
COMPLETED
|
149
|
148
|
|
Overall Study
NOT COMPLETED
|
5
|
4
|
Reasons for withdrawal
| Measure |
VVC Option
Option to receive VA Video Connect (VVC) delivery of HIV care.
VVC: Telehealth treatment is delivered via VA-approved technology to a patient's computer or mobile device.
|
Usual Care
All HIV care available at MEDVAMC will be delivered as usual.
|
|---|---|---|
|
Overall Study
Death
|
3
|
4
|
|
Overall Study
Moved to a different clinic
|
2
|
0
|
Baseline Characteristics
One participant had missing data and was excluded from the analysis.
Baseline characteristics by cohort
| Measure |
VVC Option
n=154 Participants
Option to receive VA Video Connect (VVC) delivery of HIV care.
VVC: Telehealth treatment is delivered via VA-approved technology to a patient's computer or mobile device.
|
Usual Care
n=152 Participants
All HIV care available at MEDVAMC will be delivered as usual.
|
Total
n=306 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Continuous
|
57.36 years
STANDARD_DEVIATION 12.59 • n=154 Participants
|
58.16 years
STANDARD_DEVIATION 12.93 • n=152 Participants
|
57.76 years
STANDARD_DEVIATION 12.74 • n=306 Participants
|
|
Sex/Gender, Customized
Female
|
4 Participants
n=154 Participants
|
4 Participants
n=152 Participants
|
8 Participants
n=306 Participants
|
|
Sex/Gender, Customized
Male
|
150 Participants
n=154 Participants
|
147 Participants
n=152 Participants
|
297 Participants
n=306 Participants
|
|
Sex/Gender, Customized
Transgender
|
0 Participants
n=154 Participants
|
1 Participants
n=152 Participants
|
1 Participants
n=306 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
13 Participants
n=154 Participants
|
17 Participants
n=152 Participants
|
30 Participants
n=306 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
139 Participants
n=154 Participants
|
133 Participants
n=152 Participants
|
272 Participants
n=306 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
2 Participants
n=154 Participants
|
2 Participants
n=152 Participants
|
4 Participants
n=306 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=154 Participants
|
0 Participants
n=152 Participants
|
0 Participants
n=306 Participants
|
|
Race (NIH/OMB)
Asian
|
0 Participants
n=154 Participants
|
1 Participants
n=152 Participants
|
1 Participants
n=306 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
1 Participants
n=154 Participants
|
2 Participants
n=152 Participants
|
3 Participants
n=306 Participants
|
|
Race (NIH/OMB)
Black or African American
|
102 Participants
n=154 Participants
|
92 Participants
n=152 Participants
|
194 Participants
n=306 Participants
|
|
Race (NIH/OMB)
White
|
50 Participants
n=154 Participants
|
53 Participants
n=152 Participants
|
103 Participants
n=306 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=154 Participants
|
0 Participants
n=152 Participants
|
0 Participants
n=306 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
1 Participants
n=154 Participants
|
4 Participants
n=152 Participants
|
5 Participants
n=306 Participants
|
|
Region of Enrollment
United States
|
154 Participants
n=154 Participants
|
152 Participants
n=152 Participants
|
306 Participants
n=306 Participants
|
|
Rural zip code
Rural
|
14 Participants
n=153 Participants • One participant had missing data and was excluded from the analysis.
|
13 Participants
n=152 Participants • One participant had missing data and was excluded from the analysis.
|
27 Participants
n=305 Participants • One participant had missing data and was excluded from the analysis.
|
|
Rural zip code
Not rural
|
139 Participants
n=153 Participants • One participant had missing data and was excluded from the analysis.
|
139 Participants
n=152 Participants • One participant had missing data and was excluded from the analysis.
|
278 Participants
n=305 Participants • One participant had missing data and was excluded from the analysis.
|
|
OEF/OIF Status
OEF/OIF
|
67 Participants
n=153 Participants • 3 participants were missing data and were excluded from the analysis
|
63 Participants
n=150 Participants • 3 participants were missing data and were excluded from the analysis
|
130 Participants
n=303 Participants • 3 participants were missing data and were excluded from the analysis
|
|
OEF/OIF Status
Not OEF/OIF
|
86 Participants
n=153 Participants • 3 participants were missing data and were excluded from the analysis
|
87 Participants
n=150 Participants • 3 participants were missing data and were excluded from the analysis
|
173 Participants
n=303 Participants • 3 participants were missing data and were excluded from the analysis
|
|
Drive time to MEDVAMC
|
37.43 minutes
STANDARD_DEVIATION 29.33 • n=148 Participants • 11 participants with missing data were excluded from this analysis
|
37.49 minutes
STANDARD_DEVIATION 31.36 • n=147 Participants • 11 participants with missing data were excluded from this analysis
|
37.46 minutes
STANDARD_DEVIATION 30.30 • n=295 Participants • 11 participants with missing data were excluded from this analysis
|
|
Alcohol Use Disorders Identification Test (AUDIT-C )
|
1.61 Score on screening tool
STANDARD_DEVIATION 2.26 • n=137 Participants • 46 participants who were missing AUDIT-C scores were excluded from this analysis.
|
1.61 Score on screening tool
STANDARD_DEVIATION 2.00 • n=123 Participants • 46 participants who were missing AUDIT-C scores were excluded from this analysis.
|
1.61 Score on screening tool
STANDARD_DEVIATION 2.14 • n=260 Participants • 46 participants who were missing AUDIT-C scores were excluded from this analysis.
|
|
Alcohol Use Disorders Identification Test (AUDIT-C )
Low-risk (0-4)
|
119 Participants
n=137 Participants • 46 participants who were missing AUDIT-C scores were excluded from this analysis.
|
103 Participants
n=123 Participants • 46 participants who were missing AUDIT-C scores were excluded from this analysis.
|
222 Participants
n=260 Participants • 46 participants who were missing AUDIT-C scores were excluded from this analysis.
|
|
Alcohol Use Disorders Identification Test (AUDIT-C )
Positive/Moderate or higher risk (>=5)
|
18 Participants
n=137 Participants • 46 participants who were missing AUDIT-C scores were excluded from this analysis.
|
20 Participants
n=123 Participants • 46 participants who were missing AUDIT-C scores were excluded from this analysis.
|
38 Participants
n=260 Participants • 46 participants who were missing AUDIT-C scores were excluded from this analysis.
|
|
Patient Health Questionnaire-2 (PHQ-2)
|
0.5 Scale score
STANDARD_DEVIATION 1.27 • n=98 Participants • 116 participants who were missing PHQ-2 scores were excluded from this analysis
|
0.62 Scale score
STANDARD_DEVIATION 1.45 • n=92 Participants • 116 participants who were missing PHQ-2 scores were excluded from this analysis
|
0.56 Scale score
STANDARD_DEVIATION 1.36 • n=190 Participants • 116 participants who were missing PHQ-2 scores were excluded from this analysis
|
|
Patient Health Questionnaire-2 (PHQ-2)
Score 0-2
|
89 Participants
n=98 Participants • 116 participants who were missing PHQ-2 scores were excluded from this analysis
|
85 Participants
n=92 Participants • 116 participants who were missing PHQ-2 scores were excluded from this analysis
|
174 Participants
n=190 Participants • 116 participants who were missing PHQ-2 scores were excluded from this analysis
|
|
Patient Health Questionnaire-2 (PHQ-2)
Score 3-6 (likely MDD)
|
9 Participants
n=98 Participants • 116 participants who were missing PHQ-2 scores were excluded from this analysis
|
7 Participants
n=92 Participants • 116 participants who were missing PHQ-2 scores were excluded from this analysis
|
16 Participants
n=190 Participants • 116 participants who were missing PHQ-2 scores were excluded from this analysis
|
|
CD4 Cell count
<200
|
3 Participants
n=46 Participants • 215 participants were missing CD4 cell count data and were excluded from this analysis
|
2 Participants
n=45 Participants • 215 participants were missing CD4 cell count data and were excluded from this analysis
|
5 Participants
n=91 Participants • 215 participants were missing CD4 cell count data and were excluded from this analysis
|
|
CD4 Cell count
200-499
|
9 Participants
n=46 Participants • 215 participants were missing CD4 cell count data and were excluded from this analysis
|
15 Participants
n=45 Participants • 215 participants were missing CD4 cell count data and were excluded from this analysis
|
24 Participants
n=91 Participants • 215 participants were missing CD4 cell count data and were excluded from this analysis
|
|
CD4 Cell count
>=500
|
34 Participants
n=46 Participants • 215 participants were missing CD4 cell count data and were excluded from this analysis
|
28 Participants
n=45 Participants • 215 participants were missing CD4 cell count data and were excluded from this analysis
|
62 Participants
n=91 Participants • 215 participants were missing CD4 cell count data and were excluded from this analysis
|
|
HIV Viral Load
<200 (suppressed)
|
136 Participants
n=152 Participants • 6 participants were missing HIV viral load data and were excluded from this analysis
|
133 Participants
n=148 Participants • 6 participants were missing HIV viral load data and were excluded from this analysis
|
269 Participants
n=300 Participants • 6 participants were missing HIV viral load data and were excluded from this analysis
|
|
HIV Viral Load
>=200
|
16 Participants
n=152 Participants • 6 participants were missing HIV viral load data and were excluded from this analysis
|
15 Participants
n=148 Participants • 6 participants were missing HIV viral load data and were excluded from this analysis
|
31 Participants
n=300 Participants • 6 participants were missing HIV viral load data and were excluded from this analysis
|
|
Antiretroviral Therapy (ART) Medication adherence
|
91.06 Percent adherence
STANDARD_DEVIATION 12.90 • n=151 Participants • 7 participants were missing medication data at baseline and were excluded from this analysis
|
91.36 Percent adherence
STANDARD_DEVIATION 14.40 • n=148 Participants • 7 participants were missing medication data at baseline and were excluded from this analysis
|
91.21 Percent adherence
STANDARD_DEVIATION 13.64 • n=299 Participants • 7 participants were missing medication data at baseline and were excluded from this analysis
|
|
Constancy Retention in Care
|
123 Participants
n=154 Participants
|
118 Participants
n=152 Participants
|
241 Participants
n=306 Participants
|
|
Completed visits for adherence counseling
|
3.84 Number of visits
STANDARD_DEVIATION 2.25 • n=154 Participants
|
3.88 Number of visits
STANDARD_DEVIATION 2.00 • n=152 Participants
|
3.86 Number of visits
STANDARD_DEVIATION 2.13 • n=306 Participants
|
|
Adherence Retention in Care
|
78.56 Percent visits attended
STANDARD_DEVIATION 21.61 • n=154 Participants • One participant was missing visit data in the 12 months prior to baseline.
|
76.72 Percent visits attended
STANDARD_DEVIATION 22.26 • n=151 Participants • One participant was missing visit data in the 12 months prior to baseline.
|
77.65 Percent visits attended
STANDARD_DEVIATION 21.92 • n=305 Participants • One participant was missing visit data in the 12 months prior to baseline.
|
PRIMARY outcome
Timeframe: From enrollment to the end of follow-up at 12 monthsPopulation: The full 306 participants were included in all analyses.
Completion of at least 1 visit with a primary care or Infectious Disease provider in each 6 months of the year at least 60 days apart.
Outcome measures
| Measure |
VVC Option
n=154 Participants
Option to receive VA Video Connect (VVC) delivery of HIV care.
VVC: Telehealth treatment is delivered via VA-approved technology to a patient's computer or mobile device.
|
Usual Care
n=152 Participants
All HIV care available at MEDVAMC will be delivered as usual.
|
|---|---|---|
|
Constancy Retention in Care Measure
|
99 Participants
|
94 Participants
|
SECONDARY outcome
Timeframe: 12 monthsPopulation: Only participants with adherence retention in care data available at baseline and the 12 month follow-up were included in descriptive and completer analyses. The 305 participants with baseline data were included in ITT analyses.
Percentage of scheduled HIV clinic appointments attended over 12 months
Outcome measures
| Measure |
VVC Option
n=152 Participants
Option to receive VA Video Connect (VVC) delivery of HIV care.
VVC: Telehealth treatment is delivered via VA-approved technology to a patient's computer or mobile device.
|
Usual Care
n=150 Participants
All HIV care available at MEDVAMC will be delivered as usual.
|
|---|---|---|
|
Adherence Retention in Care Measure
|
61.74 percentage of HIV clinic visits attended
Standard Deviation 31.35
|
66.49 percentage of HIV clinic visits attended
Standard Deviation 27.88
|
SECONDARY outcome
Timeframe: 12 monthsPopulation: The full 306 participants were included in all analyses.
Number of completed visits for counseling, mental health, and social services during the year.
Outcome measures
| Measure |
VVC Option
n=154 Participants
Option to receive VA Video Connect (VVC) delivery of HIV care.
VVC: Telehealth treatment is delivered via VA-approved technology to a patient's computer or mobile device.
|
Usual Care
n=152 Participants
All HIV care available at MEDVAMC will be delivered as usual.
|
|---|---|---|
|
Completed Visits for Adherence Counseling
|
2.55 number of visits
Standard Deviation 1.88
|
2.73 number of visits
Standard Deviation 1.64
|
SECONDARY outcome
Timeframe: 12 monthsPopulation: Only participants with viral load data available in the medical record at baseline and 12 month follow-up period were included in analyses.
Number of Veterans with HIV on ART whose most recent viral load during the 12-month period was \<200c/mL
Outcome measures
| Measure |
VVC Option
n=126 Participants
Option to receive VA Video Connect (VVC) delivery of HIV care.
VVC: Telehealth treatment is delivered via VA-approved technology to a patient's computer or mobile device.
|
Usual Care
n=135 Participants
All HIV care available at MEDVAMC will be delivered as usual.
|
|---|---|---|
|
HIV Suppression
|
121 Participants
|
128 Participants
|
SECONDARY outcome
Timeframe: 12 monthsPopulation: Only participants with medication data available at baseline and 12 month follow-up period were included in analyses.
The percentage of ART medication dispensed was calculated by dividing the total number of ART medication pills dispensed during each 365-day observation period (i.e., baseline and 12-month follow-up) by 365 and then multiplying by 100, yielding a percentage (0-100%). This pharmacy dispensing measure serves as a proxy for medication adherence, with higher percentages indicating greater medication availability.
Outcome measures
| Measure |
VVC Option
n=151 Participants
Option to receive VA Video Connect (VVC) delivery of HIV care.
VVC: Telehealth treatment is delivered via VA-approved technology to a patient's computer or mobile device.
|
Usual Care
n=145 Participants
All HIV care available at MEDVAMC will be delivered as usual.
|
|---|---|---|
|
Percent ART Medication Dispensed (as a Proxy for Medication Adherence)
|
90.30 mean percentage ART medication dispensed
Standard Deviation 14.91
|
91.32 mean percentage ART medication dispensed
Standard Deviation 13.35
|
OTHER_PRE_SPECIFIED outcome
Timeframe: 12 monthsPopulation: With 91 participants at baseline, 61 at 12 month follow-up and 17 at both assessment timepoints, imputations were not appropriate and statistical comparisons between VVC and UC arms could not be conducted.
Last recorded value in medical record during 12 month period
Outcome measures
| Measure |
VVC Option
n=10 Participants
Option to receive VA Video Connect (VVC) delivery of HIV care.
VVC: Telehealth treatment is delivered via VA-approved technology to a patient's computer or mobile device.
|
Usual Care
n=7 Participants
All HIV care available at MEDVAMC will be delivered as usual.
|
|---|---|---|
|
CD4 Cell Count Greater Than or Equal to 200
< 200
|
0 Participants
|
0 Participants
|
|
CD4 Cell Count Greater Than or Equal to 200
> = 200
|
10 Participants
|
7 Participants
|
Adverse Events
VVC Option
Serious events: 42 serious events
Other events: 62 other events
Deaths: 3 deaths
Usual Care
Serious events: 38 serious events
Other events: 61 other events
Deaths: 4 deaths
Serious adverse events
| Measure |
VVC Option
n=154 participants at risk
Option to receive VA Video Connect (VVC) delivery of HIV care.
VVC: Telehealth treatment is delivered via VA-approved technology to a patient's computer or mobile device.
|
Usual Care
n=152 participants at risk
All HIV care available at MEDVAMC will be delivered as usual.
|
|---|---|---|
|
Blood and lymphatic system disorders
Hospital Admission
|
0.65%
1/154 • From enrollment to end of follow-up period, up to 12 months
Adverse event information was collected via chart review of participant medical records by the study team
|
1.3%
2/152 • From enrollment to end of follow-up period, up to 12 months
Adverse event information was collected via chart review of participant medical records by the study team
|
|
Cardiac disorders
Hospital admission
|
2.6%
4/154 • From enrollment to end of follow-up period, up to 12 months
Adverse event information was collected via chart review of participant medical records by the study team
|
2.0%
3/152 • From enrollment to end of follow-up period, up to 12 months
Adverse event information was collected via chart review of participant medical records by the study team
|
|
Endocrine disorders
Hospital Admission
|
0.65%
1/154 • From enrollment to end of follow-up period, up to 12 months
Adverse event information was collected via chart review of participant medical records by the study team
|
0.00%
0/152 • From enrollment to end of follow-up period, up to 12 months
Adverse event information was collected via chart review of participant medical records by the study team
|
|
Gastrointestinal disorders
Hospital Admission
|
1.9%
3/154 • From enrollment to end of follow-up period, up to 12 months
Adverse event information was collected via chart review of participant medical records by the study team
|
1.3%
2/152 • From enrollment to end of follow-up period, up to 12 months
Adverse event information was collected via chart review of participant medical records by the study team
|
|
General disorders
Hospital Admission
|
2.6%
4/154 • From enrollment to end of follow-up period, up to 12 months
Adverse event information was collected via chart review of participant medical records by the study team
|
1.3%
2/152 • From enrollment to end of follow-up period, up to 12 months
Adverse event information was collected via chart review of participant medical records by the study team
|
|
Hepatobiliary disorders
Hospital Admission
|
0.65%
1/154 • From enrollment to end of follow-up period, up to 12 months
Adverse event information was collected via chart review of participant medical records by the study team
|
0.66%
1/152 • From enrollment to end of follow-up period, up to 12 months
Adverse event information was collected via chart review of participant medical records by the study team
|
|
Infections and infestations
Hospital Admission
|
2.6%
4/154 • From enrollment to end of follow-up period, up to 12 months
Adverse event information was collected via chart review of participant medical records by the study team
|
1.3%
2/152 • From enrollment to end of follow-up period, up to 12 months
Adverse event information was collected via chart review of participant medical records by the study team
|
|
Injury, poisoning and procedural complications
Hospital Admission
|
0.00%
0/154 • From enrollment to end of follow-up period, up to 12 months
Adverse event information was collected via chart review of participant medical records by the study team
|
0.66%
1/152 • From enrollment to end of follow-up period, up to 12 months
Adverse event information was collected via chart review of participant medical records by the study team
|
|
Metabolism and nutrition disorders
Hospital Admission
|
0.65%
1/154 • From enrollment to end of follow-up period, up to 12 months
Adverse event information was collected via chart review of participant medical records by the study team
|
0.00%
0/152 • From enrollment to end of follow-up period, up to 12 months
Adverse event information was collected via chart review of participant medical records by the study team
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hospital Admission
|
0.00%
0/154 • From enrollment to end of follow-up period, up to 12 months
Adverse event information was collected via chart review of participant medical records by the study team
|
1.3%
2/152 • From enrollment to end of follow-up period, up to 12 months
Adverse event information was collected via chart review of participant medical records by the study team
|
|
Nervous system disorders
Hospital Admission
|
1.9%
3/154 • From enrollment to end of follow-up period, up to 12 months
Adverse event information was collected via chart review of participant medical records by the study team
|
1.3%
2/152 • From enrollment to end of follow-up period, up to 12 months
Adverse event information was collected via chart review of participant medical records by the study team
|
|
Psychiatric disorders
Hospital Admission
|
0.00%
0/154 • From enrollment to end of follow-up period, up to 12 months
Adverse event information was collected via chart review of participant medical records by the study team
|
2.6%
4/152 • From enrollment to end of follow-up period, up to 12 months
Adverse event information was collected via chart review of participant medical records by the study team
|
|
Renal and urinary disorders
Hospital Admission
|
2.6%
4/154 • From enrollment to end of follow-up period, up to 12 months
Adverse event information was collected via chart review of participant medical records by the study team
|
2.6%
4/152 • From enrollment to end of follow-up period, up to 12 months
Adverse event information was collected via chart review of participant medical records by the study team
|
|
Respiratory, thoracic and mediastinal disorders
Hospital Admission
|
1.3%
2/154 • From enrollment to end of follow-up period, up to 12 months
Adverse event information was collected via chart review of participant medical records by the study team
|
0.00%
0/152 • From enrollment to end of follow-up period, up to 12 months
Adverse event information was collected via chart review of participant medical records by the study team
|
|
Skin and subcutaneous tissue disorders
Hospital Admission
|
0.00%
0/154 • From enrollment to end of follow-up period, up to 12 months
Adverse event information was collected via chart review of participant medical records by the study team
|
0.66%
1/152 • From enrollment to end of follow-up period, up to 12 months
Adverse event information was collected via chart review of participant medical records by the study team
|
|
Surgical and medical procedures
Hospital Admission
|
5.2%
8/154 • From enrollment to end of follow-up period, up to 12 months
Adverse event information was collected via chart review of participant medical records by the study team
|
5.3%
8/152 • From enrollment to end of follow-up period, up to 12 months
Adverse event information was collected via chart review of participant medical records by the study team
|
|
Vascular disorders
Hospital Admission
|
0.65%
1/154 • From enrollment to end of follow-up period, up to 12 months
Adverse event information was collected via chart review of participant medical records by the study team
|
0.00%
0/152 • From enrollment to end of follow-up period, up to 12 months
Adverse event information was collected via chart review of participant medical records by the study team
|
|
Cardiac disorders
Emergency Room Visit
|
0.65%
1/154 • From enrollment to end of follow-up period, up to 12 months
Adverse event information was collected via chart review of participant medical records by the study team
|
0.66%
1/152 • From enrollment to end of follow-up period, up to 12 months
Adverse event information was collected via chart review of participant medical records by the study team
|
|
Endocrine disorders
Emergency Room Visit
|
0.00%
0/154 • From enrollment to end of follow-up period, up to 12 months
Adverse event information was collected via chart review of participant medical records by the study team
|
0.66%
1/152 • From enrollment to end of follow-up period, up to 12 months
Adverse event information was collected via chart review of participant medical records by the study team
|
|
Infections and infestations
Emergency Room Visit
|
0.65%
1/154 • From enrollment to end of follow-up period, up to 12 months
Adverse event information was collected via chart review of participant medical records by the study team
|
0.00%
0/152 • From enrollment to end of follow-up period, up to 12 months
Adverse event information was collected via chart review of participant medical records by the study team
|
|
Injury, poisoning and procedural complications
Emergency Room Visit
|
0.65%
1/154 • From enrollment to end of follow-up period, up to 12 months
Adverse event information was collected via chart review of participant medical records by the study team
|
0.66%
1/152 • From enrollment to end of follow-up period, up to 12 months
Adverse event information was collected via chart review of participant medical records by the study team
|
|
Nervous system disorders
Emergency Room Visit
|
1.3%
2/154 • From enrollment to end of follow-up period, up to 12 months
Adverse event information was collected via chart review of participant medical records by the study team
|
0.66%
1/152 • From enrollment to end of follow-up period, up to 12 months
Adverse event information was collected via chart review of participant medical records by the study team
|
Other adverse events
| Measure |
VVC Option
n=154 participants at risk
Option to receive VA Video Connect (VVC) delivery of HIV care.
VVC: Telehealth treatment is delivered via VA-approved technology to a patient's computer or mobile device.
|
Usual Care
n=152 participants at risk
All HIV care available at MEDVAMC will be delivered as usual.
|
|---|---|---|
|
Musculoskeletal and connective tissue disorders
Emergency Room Visit
|
5.8%
9/154 • From enrollment to end of follow-up period, up to 12 months
Adverse event information was collected via chart review of participant medical records by the study team
|
5.9%
9/152 • From enrollment to end of follow-up period, up to 12 months
Adverse event information was collected via chart review of participant medical records by the study team
|
|
Nervous system disorders
Emergency Room Visit
|
0.00%
0/154 • From enrollment to end of follow-up period, up to 12 months
Adverse event information was collected via chart review of participant medical records by the study team
|
2.6%
4/152 • From enrollment to end of follow-up period, up to 12 months
Adverse event information was collected via chart review of participant medical records by the study team
|
|
Psychiatric disorders
Emergency Room Visit
|
1.3%
2/154 • From enrollment to end of follow-up period, up to 12 months
Adverse event information was collected via chart review of participant medical records by the study team
|
0.66%
1/152 • From enrollment to end of follow-up period, up to 12 months
Adverse event information was collected via chart review of participant medical records by the study team
|
|
Renal and urinary disorders
Emergency Room Visit
|
1.9%
3/154 • From enrollment to end of follow-up period, up to 12 months
Adverse event information was collected via chart review of participant medical records by the study team
|
2.0%
3/152 • From enrollment to end of follow-up period, up to 12 months
Adverse event information was collected via chart review of participant medical records by the study team
|
|
Respiratory, thoracic and mediastinal disorders
Emergency Room Visit
|
7.8%
12/154 • From enrollment to end of follow-up period, up to 12 months
Adverse event information was collected via chart review of participant medical records by the study team
|
8.6%
13/152 • From enrollment to end of follow-up period, up to 12 months
Adverse event information was collected via chart review of participant medical records by the study team
|
|
Skin and subcutaneous tissue disorders
Emergency Room Visit
|
0.65%
1/154 • From enrollment to end of follow-up period, up to 12 months
Adverse event information was collected via chart review of participant medical records by the study team
|
1.3%
2/152 • From enrollment to end of follow-up period, up to 12 months
Adverse event information was collected via chart review of participant medical records by the study team
|
|
Surgical and medical procedures
Emergency Room Visit
|
0.65%
1/154 • From enrollment to end of follow-up period, up to 12 months
Adverse event information was collected via chart review of participant medical records by the study team
|
0.00%
0/152 • From enrollment to end of follow-up period, up to 12 months
Adverse event information was collected via chart review of participant medical records by the study team
|
|
Vascular disorders
Emergency Room Visit
|
1.9%
3/154 • From enrollment to end of follow-up period, up to 12 months
Adverse event information was collected via chart review of participant medical records by the study team
|
0.66%
1/152 • From enrollment to end of follow-up period, up to 12 months
Adverse event information was collected via chart review of participant medical records by the study team
|
|
Renal and urinary disorders
Hospital Admission
|
0.65%
1/154 • From enrollment to end of follow-up period, up to 12 months
Adverse event information was collected via chart review of participant medical records by the study team
|
0.00%
0/152 • From enrollment to end of follow-up period, up to 12 months
Adverse event information was collected via chart review of participant medical records by the study team
|
|
Surgical and medical procedures
Hospital Admission
|
0.65%
1/154 • From enrollment to end of follow-up period, up to 12 months
Adverse event information was collected via chart review of participant medical records by the study team
|
0.66%
1/152 • From enrollment to end of follow-up period, up to 12 months
Adverse event information was collected via chart review of participant medical records by the study team
|
|
Immune system disorders
Emergency Room Visit
|
0.65%
1/154 • From enrollment to end of follow-up period, up to 12 months
Adverse event information was collected via chart review of participant medical records by the study team
|
0.00%
0/152 • From enrollment to end of follow-up period, up to 12 months
Adverse event information was collected via chart review of participant medical records by the study team
|
|
Infections and infestations
Emergency Room Visit
|
4.5%
7/154 • From enrollment to end of follow-up period, up to 12 months
Adverse event information was collected via chart review of participant medical records by the study team
|
2.6%
4/152 • From enrollment to end of follow-up period, up to 12 months
Adverse event information was collected via chart review of participant medical records by the study team
|
|
Injury, poisoning and procedural complications
Emergency Room Visit
|
2.6%
4/154 • From enrollment to end of follow-up period, up to 12 months
Adverse event information was collected via chart review of participant medical records by the study team
|
1.3%
2/152 • From enrollment to end of follow-up period, up to 12 months
Adverse event information was collected via chart review of participant medical records by the study team
|
|
Psychiatric disorders
Psychosis leading to ART medication noncompliance
|
0.00%
0/154 • From enrollment to end of follow-up period, up to 12 months
Adverse event information was collected via chart review of participant medical records by the study team
|
0.66%
1/152 • From enrollment to end of follow-up period, up to 12 months
Adverse event information was collected via chart review of participant medical records by the study team
|
|
Psychiatric disorders
Crisis Call
|
1.3%
2/154 • From enrollment to end of follow-up period, up to 12 months
Adverse event information was collected via chart review of participant medical records by the study team
|
2.0%
3/152 • From enrollment to end of follow-up period, up to 12 months
Adverse event information was collected via chart review of participant medical records by the study team
|
|
Respiratory, thoracic and mediastinal disorders
Illness
|
0.65%
1/154 • From enrollment to end of follow-up period, up to 12 months
Adverse event information was collected via chart review of participant medical records by the study team
|
0.00%
0/152 • From enrollment to end of follow-up period, up to 12 months
Adverse event information was collected via chart review of participant medical records by the study team
|
|
Surgical and medical procedures
Invasive Procedure
|
0.65%
1/154 • From enrollment to end of follow-up period, up to 12 months
Adverse event information was collected via chart review of participant medical records by the study team
|
0.00%
0/152 • From enrollment to end of follow-up period, up to 12 months
Adverse event information was collected via chart review of participant medical records by the study team
|
|
Cardiac disorders
Emergency Room Visit
|
1.3%
2/154 • From enrollment to end of follow-up period, up to 12 months
Adverse event information was collected via chart review of participant medical records by the study team
|
0.66%
1/152 • From enrollment to end of follow-up period, up to 12 months
Adverse event information was collected via chart review of participant medical records by the study team
|
|
Endocrine disorders
Emergency Room Visit
|
0.00%
0/154 • From enrollment to end of follow-up period, up to 12 months
Adverse event information was collected via chart review of participant medical records by the study team
|
0.66%
1/152 • From enrollment to end of follow-up period, up to 12 months
Adverse event information was collected via chart review of participant medical records by the study team
|
|
Eye disorders
Emergency Room Visit
|
0.65%
1/154 • From enrollment to end of follow-up period, up to 12 months
Adverse event information was collected via chart review of participant medical records by the study team
|
0.66%
1/152 • From enrollment to end of follow-up period, up to 12 months
Adverse event information was collected via chart review of participant medical records by the study team
|
|
Gastrointestinal disorders
Emergency Room Visit
|
1.3%
2/154 • From enrollment to end of follow-up period, up to 12 months
Adverse event information was collected via chart review of participant medical records by the study team
|
2.0%
3/152 • From enrollment to end of follow-up period, up to 12 months
Adverse event information was collected via chart review of participant medical records by the study team
|
|
General disorders
Emergency Room Visit
|
5.2%
8/154 • From enrollment to end of follow-up period, up to 12 months
Adverse event information was collected via chart review of participant medical records by the study team
|
7.2%
11/152 • From enrollment to end of follow-up period, up to 12 months
Adverse event information was collected via chart review of participant medical records by the study team
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place